Myungmoon acquires approval of its stomach and head & neck cancer treatment as ‘first generic’
Myungmoon Pharm, which has recently concentrated its capacity into the anticancer drug business, acquired approval of its stomach cancer and head & neck cancer treatments, ‘Tego Cap 20 and Tego Cap 25,’ from the Ministry of Food and Drug Safety(MFDS) from the 31st of August through a strategic pa...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
